Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study | Zendy

L. Plaisance | Zendy; Céline Chapelle | Zendy; Silvy Laporte | Zendy; Benjamin Planquette | Zendy; Laurent Bertoletti | Zendy; Nicolas Falvo | Zendy; Françis Couturaud | Zendy; L. Falchero | Zendy; I. Mahé | Zendy; H. L. Helfer | Zendy; Sadji Dennaoui | Zendy; Guy Meyer | Zendy; Isabelle Mahé | Zendy

Open Access

Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study

Author(s) -

L. Plaisance,

Céline Chapelle,

Silvy Laporte,

Benjamin Planquette,

Laurent Bertoletti,

Nicolas Falvo,

Françis Couturaud,

L. Falchero,

I. Mahé,

H. L. Helfer,

Sadji Dennaoui,

Guy Meyer,

Isabelle Mahé

Publication year - 2021

Publication title -

journal of cancer science and clinical therapeutics

Language(s) - English

Resource type - Journals

ISSN - 2637-5079

DOI - 10.26502/jcsct.5079122

Subject(s) - medicine , vitamin k antagonist , anticoagulant , retrospective cohort study , thrombosis , anticoagulant therapy , cancer , surgery , warfarin , atrial fibrillation

Few data are available about anticoagulation management beyond 6 months in patients with cancer associated thrombosis (CAT). Our objective was to describe anticoagulant treatment modalities up to 12 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research